CEBINA uniquely supports life science entrepreneurs and early-stage start-up companies and develops cutting-edge biotech projects


CEBINA was founded with the aim of creating, nurturing, and promoting early-stage life sciences companies, to develop new medicines and cutting-edge technologies.


With decades-long experience in pharmaceutical product development and biotech entrepreneurship, our team supports our internal projects and resident companies with cutting edge facilities and tailor-made services throughout all stages of company development.


For each new project, CEBINA undertakes extensive due diligence to identify projects with the highest potential, offering attractive, de-risked opportunities for investors.

CEBINA covid square.png

10 December 2021

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more

CEBINA covid square.png

17 August 2021

Widely available anti-allergy azelastine nasal spray poised to revolutionise COVID-19 management

Read more


DL square for CEBINA website.png

14 June 2021

CEBINA announces the launch of Danube Labs, a partnership with Evotec to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions

Read more


Karl-Farkas-Gasse 22

1030 Vienna, Austria